Sanofi-Aventis Korea (CEO: Bae Eun Bae) announced on the 8th that the salary standard for Obagio® film coated tablets (ingredient name: teriflunomide), its first-line treatment for multiple sclerosis, has been expanded.
Obaggio® was examined by a neurologist according to the’Details on the application standards and methods of medical care benefits (pharmaceuticals)’ announced by the Ministry of Health and Welfare on January 29, In time, DIT) and dissemination in space (DIS)), the benefit target is expanded to patients with relapsed multiple sclerosis (RRMS) who can go to the outpatient hospital to exclude the occurrence of other similar diseases. done.
The core of this amendment is that the wage standard can be determined by experts based on the McDonald diagnosis standard, which is the standard diagnosis standard for multiple sclerosis. Restrictive provisions that allowed salaries to be applied have been removed. The company explained that this will allow patients with multiple sclerosis to receive benefits from Obagio® earlier, which will greatly improve access to treatment.
Obagio® is an oral first-line treatment that reduces the burden of self-injection in patients with relapsed multiple sclerosis. The once-a-day administration method can help increase the adherence to treatment in patients with multiple sclerosis who need long-term continuous treatment. Obazio® is a cytostatic mechanism that reduces the number of activated lymphocytes in the peripheral immune system, suppresses the recurrence of multiple sclerosis, while maintaining normal immune function, and has consistent safety data for over 16 years. have.